Patents by Inventor Shawn Wells

Shawn Wells has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11026991
    Abstract: The disclosed compositions and methods relate to the increasing muscle mass, preventing muscle atrophy, promoting muscle growth, as well as treatment of various other conditions and diseases. In certain aspects, the disclosed compositions are comprised dileucine and leucine and pharmaceutically acceptable salts thereof. In certain aspects, disclosed compositions are administered to subjects in need thereof to increase muscle mass, prevent muscle atrophy, and/or promote muscle growth.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: June 8, 2021
    Assignee: Ingenious Ingredients, LP
    Inventors: Martin Purpura, Ralf Jaeger, Shawn Wells, Kylin Lao, Anton Fliri
  • Publication number: 20200315997
    Abstract: The present disclosure pertains to compositions and methods for the treatment and/or prevention of one or more of obesity, diabetes, metabolic syndrome, Alzheimer's disease, Chronic Fatigue Syndrome (CFS), aging, fibromyalgia, dyslipidemia, hypercholesterolemia, dyslipidemia, Parkinson's disease, migraines, Traumatic Brain Injury (TBI), Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD), Cancer, Cardiovascular Disease (CVD)/Coronary Artery Disease (CAD), Chronic Pain, neuralgia, depression, amyotrophic lateral sclerosis (ALS), and epilepsy, Insufficient Cellular Energy (ICE) and mitochondrial dysfunction. The present disclosure also pertains to methods for increasing mental and/or physical performance levels and/or decreasing exertion during exercise in a subject by the administration of C5 ketones.
    Type: Application
    Filed: August 1, 2017
    Publication date: October 8, 2020
    Inventors: Ryan P. Lowery, Shawn Wells, Jacob Wilson, Kylin Liao
  • Publication number: 20190374546
    Abstract: A human dietary supplement comprises theacrine and optionally other compounds that modulate the effects of theacrine. Uses for the theacrine-containing supplement include improvement of at least one of mood, energy, focus, concentration or sexual desire or a reduction of at least one of anxiety or fatigue. A synergistic composition comprises co-administration of theacrine and caffeine, wherein the co-administered caffeine reduces theacrine oral clearance (CL/F) and oral volume of distribution (Vd/F). In addition, the co-administered caffeine increases area under the plasma concentration time curve (AUC) of theacrine, and increases theacrine maximum plasma concentration (Cmax) in comparison with the corresponding pharmacokinetic parameters when theacrine is administered alone.
    Type: Application
    Filed: August 26, 2019
    Publication date: December 12, 2019
    Applicant: Ortho-Nutra, LLC
    Inventors: Hector L. Lopez, Shawn Wells, Tim N. Ziegenfuss
  • Publication number: 20190321437
    Abstract: The disclosed compositions and methods relate to the increasing muscle mass, preventing muscle atrophy, promoting muscle growth, as well as treatment of various other conditions and diseases. In certain aspects, the disclosed compositions are comprised dileucine and leucine and pharmaceutically acceptable salts thereof. In certain aspects, disclosed compositions are administered to subjects in need thereof to increase muscle mass, prevent muscle atrophy, and/or promote muscle growth.
    Type: Application
    Filed: April 18, 2019
    Publication date: October 24, 2019
    Inventors: Martin Purpura, Ralf Jaeger, Shawn Wells, Kylin Lao, Anton Fliri
  • Patent number: 10398701
    Abstract: A human dietary supplement comprises theacrine and optionally other compounds that modulate the effects of theacrine. Uses for the theacrine-containing supplement include improvement of at least one of mood, energy, focus, concentration or sexual desire or a reduction of at least one of anxiety or fatigue. A synergistic composition comprises co-administration of theacrine and caffeine, wherein the co-administered caffeine reduces theacrine oral clearance (CL/F) and oral volume of distribution (Vd/F). In addition, the co-administered caffeine increases area under the plasma concentration time curve (AUC) of theacrine, and increases theacrine maximum plasma concentration (Cmax) in comparison with the corresponding pharmacokinetic parameters when theacrine is administered alone.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: September 3, 2019
    Assignee: Ortho-Nutra, LLC
    Inventors: Hector L. Lopez, Shawn Wells, Tim N. Ziegenfuss
  • Publication number: 20190255028
    Abstract: In various implementations, berberine metabolites, such as dihydroberberine and/or tetrahydroberberine, may be administered to manage blood glucose levels, increase ketone levels (e.g., blood concentration of ketones), and/or for therapeutic purposes in humans. The administration of a pharmaceutically effective amount of berberine metabolites, such as dihydroberberine, may reduce fasting blood glucose levels, improve glucose tolerance, and/or improve blood ketone response. In some implementations, berberine metabolites may be administered with one or more other compounds.
    Type: Application
    Filed: May 6, 2019
    Publication date: August 22, 2019
    Inventors: Ryan Lowery, Jacob Wilson, Shawn Wells, Terry LaCore
  • Patent number: 10278961
    Abstract: In various implementations, berberine metabolites, such as dihydroberberine and/or tetrahydroberberine, may be administered to manage blood glucose levels, increase ketone levels (e.g., blood concentration of ketones), and/or for therapeutic purposes in humans. The administration of a pharmaceutically effective amount of berberine metabolites, such as dihydroberberine, may reduce fasting blood glucose levels, improve glucose tolerance, and/or improve blood ketone response. In some implementations, berberine metabolites may be administered with one or more other compounds.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: May 7, 2019
    Assignee: Keto Patent Group, Inc.
    Inventors: Ryan Lowery, Jacob Wilson, Shawn Wells, Terry LaCore
  • Patent number: 10272091
    Abstract: A human dietary supplement comprises theacrine and optionally other compounds that modulate the effects of theacrine. Uses for the theacrine-containing supplement include improvement of at least one of mood, energy, focus, concentration or sexual desire or a reduction of at least one of anxiety or fatigue.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: April 30, 2019
    Assignee: Ortho-Nutra, LLC
    Inventors: Hector L Lopez, Shawn Wells, Tim N. Ziegenfuss
  • Publication number: 20180104248
    Abstract: A human dietary supplement comprises theacrine and optionally other compounds that modulate the effects of theacrine. Uses for the theacrine-containing supplement include improvement of at least one of mood, energy, focus, concentration or sexual desire or a reduction of at least one of anxiety or fatigue. A synergistic composition comprises co-administration of theacrine and caffeine, wherein the co-administered caffeine reduces theacrine oral clearance (CL/F) and oral volume of distribution (Vd/F). In addition, the co-administered caffeine increases area under the plasma concentration time curve (AUC) of theacrine, and increases theacrine maximum plasma concentration (Cmax) in comparison with the corresponding pharmacokinetic parameters when theacrine is administered alone.
    Type: Application
    Filed: May 19, 2017
    Publication date: April 19, 2018
    Applicant: Ortho-Nutra, LLC
    Inventors: Hector L Lopez, Shawn Wells, Tim N. Ziegenfuss
  • Publication number: 20170296501
    Abstract: In various implementations, beta-hydroxybutyrate, related compounds, and/or one or more other compounds may be administered to an individual to cause weight loss, weight maintenance, elevate blood ketone levels, maintain blood ketone levels, reduce blood glucose levels, maintain blood glucose levels, improve energy, focus, mood, cognitive function, or aide with neurological or inflammatory disorders and/or combinations thereof. Other compounds may include short chain fatty acids, short chain triglycerides, medium chain fatty acids, medium chain triglycerides, long chain fatty acids, long chain triglycerides, berberine, metabolites of berberine (e.g., dihydroberberine), and/or combinations thereof.
    Type: Application
    Filed: April 19, 2017
    Publication date: October 19, 2017
    Inventors: Ryan Lowery, Jacob Wilson, Shawn Wells, Brian Underwood, Christopher N. Harding, Terry LaCore
  • Publication number: 20170296520
    Abstract: In various implementations, berberine metabolites, such as dihydroberberine and/or tetrahydroberberine, may be administered to manage blood glucose levels, increase ketone levels (e.g., blood concentration of ketones), and/or for therapeutic purposes in humans. The administration of a pharmaceutically effective amount of berberine metabolites, such as dihydroberberine, may reduce fasting blood glucose levels, improve glucose tolerance, and/or improve blood ketone response. In some implementations, berberine metabolites may be administered with one or more other compounds.
    Type: Application
    Filed: April 19, 2017
    Publication date: October 19, 2017
    Inventors: Ryan Lowery, Jacob Wilson, Shawn Wells, Brian Underwood, Christopher N. Harding, Terry LaCore
  • Publication number: 20150132280
    Abstract: A human dietary supplement comprises theacrine and optionally other compounds that modulate the effects of theacrine. Uses for the theacrine-containing supplement include improvement of at least one of mood, energy, focus, concentration or sexual desire or a reduction of at least one of anxiety or fatigue.
    Type: Application
    Filed: November 12, 2014
    Publication date: May 14, 2015
    Applicant: ORTHO-NUTRA, LLC
    Inventors: Hector L Lopez, Shawn Wells, Tim N. Ziegenfuss
  • Publication number: 20110144040
    Abstract: The present invention relates to increasing the athletic performance of humans using acteoside. This may be in the form of a pure compound, or plant extracts containing at least 10% acteoside by weight. Application of this invention provides increased strength, muscle power, endurance, muscle protein content, and reduced fatigue.
    Type: Application
    Filed: December 8, 2010
    Publication date: June 16, 2011
    Inventors: Shawn Wells, William C. Llewellyn
  • Publication number: 20110142964
    Abstract: The present invention relates to increasing the athletic performance of humans, using ruta chalepensis extract as an oral supplement or medicine. Use of the invention provides increased muscle strength, muscle power, endurance, muscle protein content, and/or reduced fatigue following exercise or competition.
    Type: Application
    Filed: December 8, 2010
    Publication date: June 16, 2011
    Inventors: Shawn Wells, William C. Llewellyn